Cannabis use and risk of schizophrenia: a Mendelian randomization study

Autor: Wei Gan, Julien Vaucher, Guillaume Paré, Aurélie M. Lasserre, Brendan J. Keating, Michael V. Holmes, Daniel J. Smith, Naveed Sattar, Joey Ward, Jill P. Pell, Donald M. Lyall
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
Marijuana Abuse
law.invention
Random Allocation
0302 clinical medicine
Randomized controlled trial
law
Risk Factors
Epidemiology
030212 general & internal medicine
Smokers
biology
Cannabis use
Middle Aged
Adult
Cannabis/metabolism
Case-Control Studies
European Continental Ancestry Group/genetics
Female
Genetic Variation
Humans
Marijuana Abuse/genetics
Marijuana Abuse/psychology
Marijuana Smoking/adverse effects
Marijuana Smoking/genetics
Marijuana Smoking/psychology
Polymorphism
Single Nucleotide
Schizophrenia/etiology
Schizophrenia/genetics
Smokers/psychology
3. Good health
Psychiatry and Mental health
Schizophrenia
Original Article
Psychopharmacology
Psychology
Clinical psychology
medicine.medical_specialty
Marijuana Smoking
White People
Cellular and Molecular Neuroscience
03 medical and health sciences
Mendelian randomization
medicine
Psychiatry
Molecular Biology
Cannabis
business.industry
Public health
Case-control study
Odds ratio
medicine.disease
biology.organism_classification
Mental health
030227 psychiatry
Observational study
business
030217 neurology & neurosurgery
Zdroj: Molecular Psychiatry
Molecular psychiatry, vol. 23, no. 5, pp. 1287-1292
ISSN: 1476-5578
1359-4184
Popis: Cannabis use is observationally associated with an increased risk of schizophrenia, but whether the relationship is causal is not known. Using a genetic approach, we took 10 independent genetic variants previously identified to associate with cannabis use in 32 330 individuals to determine the nature of the association between cannabis use and risk of schizophrenia. Genetic variants were employed as instruments to recapitulate a randomized controlled trial involving two groups (cannabis users vs nonusers) to estimate the causal effect of cannabis use on risk of schizophrenia in 34 241 cases and 45 604 controls from predominantly European descent. Genetically-derived estimates were compared with a meta-analysis of observational studies reporting ever use of cannabis and risk of schizophrenia or related disorders. Based on the genetic approach, use of cannabis was associated with increased risk of schizophrenia (odds ratio (OR) of schizophrenia for users vs nonusers of cannabis: 1.37; 95% confidence interval (CI), 1.09-1.67; P-value=0.007). The corresponding estimate from observational analysis was 1.43 (95% CI, 1.19-1.67; P-value for heterogeneity =0.76). The genetic markers did not show evidence of pleiotropic effects and accounting for tobacco exposure did not alter the association (OR of schizophrenia for users vs nonusers of cannabis, adjusted for ever vs never smoker: 1.41; 95% CI, 1.09-1.83). This adds to the substantial evidence base that has previously identified cannabis use to associate with increased risk of schizophrenia, by suggesting that the relationship is causal. Such robust evidence may inform public health messages about cannabis use, especially regarding its potential mental health consequences.Molecular Psychiatry advance online publication, 24 January 2017; doi:10.1038/mp.2016.252.
Databáze: OpenAIRE
Externí odkaz: